These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18571380)

  • 1. Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?
    Ludlam HA; Enoch DA
    Int J Antimicrob Agents; 2008 Aug; 32(2):101-5. PubMed ID: 18571380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials.
    Yuan X; Liang BB; Wang R; Liu YN; Sun CG; Cai Y; Yu XH; Bai N; Zhao TM; Cui JC; Chen LA
    J Chemother; 2012 Oct; 24(5):257-67. PubMed ID: 23182045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial].
    Jardim JR; Rico G; de la Roza C; Obispo E; Urueta J; Wolff M; Miravitlles M;
    Arch Bronconeumol; 2003 Sep; 39(9):387-93. PubMed ID: 12975069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of moxifloxacin in the treatment of community-acquired pneumonia].
    Máthé A; Tóth K; Kovács G
    Orv Hetil; 2004 Oct; 145(44):2227-30. PubMed ID: 15626167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
    Wispelwey B; Schafer KR
    Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
    Martinez FJ
    Clin Infect Dis; 2004 May; 38 Suppl 4():S328-40. PubMed ID: 15127366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin: a respiratory fluoroquinolone.
    Miravitlles M; Anzueto A
    Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Q Fever pneumonia: are clarithromycin and moxifloxacin alternative treatments only?
    Morovic M
    Am J Trop Med Hyg; 2005 Nov; 73(5):947-8. PubMed ID: 16282309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
    An MM; Zou Z; Shen H; Gao PH; Cao YB; Jiang YY
    Int J Antimicrob Agents; 2010 Jul; 36(1):58-65. PubMed ID: 20400271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
    Martin M; Moore L; Quilici S; Decramer M; Simoens S
    Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp.
    Garau J; Fritsch A; Arvis P; Read RC
    J Chemother; 2010 Aug; 22(4):264-6. PubMed ID: 20685631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxifloxacin in the treatment of hospitalised community acquired pneumonia in HIV-infected subjects.
    Bassetti M; Rosso R; Tosi C; DI Biagio A; Righi E; Viscoli C
    J Chemother; 2007 Feb; 19(1):104-5. PubMed ID: 17309861
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
    Katz E; Larsen LS; Fogarty CM; Hamed K; Song J; Choudhri S
    J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
    Charles PG; Whitby M; Fuller AJ; Stirling R; Wright AA; Korman TM; Holmes PW; Christiansen KJ; Waterer GW; Pierce RJ; Mayall BC; Armstrong JG; Catton MG; Nimmo GR; Johnson B; Hooy M; Grayson ML;
    Clin Infect Dis; 2008 May; 46(10):1513-21. PubMed ID: 18419484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents.
    Roig J; Casal J; Gispert P; Gea E
    Med Mal Infect; 2006; 36(11-12):680-9. PubMed ID: 17095177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.